Best Practices in Communicating and Disseminating Medical Information to External Stakeholders

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Laboratories


Companies Profiled:
Abbott; AbbVie; Amicus Therapeutics; Bayer; Boehringer Ingelheim; BTG plc; CSL Behring; Depomed; Eisai; EMD Serono; Enlyton; Glenmark; GRAIL; Grifols; Jazz Pharmaceuticals; Juno Therapeutics; Medtronic; Merck; Merz Pharma; Novartis; Novo Nordisk; Pfizer; Pierre Fabre; Santen; Shire; Vifor Pharma

Study Snapshot

Best Practices, LLC engaged 31 medical information professionals from 26 leading companies in this benchmarking research. Research analysis and recommendations are presented into two segments: Large Companies Segment and Small-Mid Sized Companies Segment.

Key topics covered in this report include:

• Methods of distribution used to disseminate information
• Types of information shared with different stakeholders
• Protection of medical information assets
• Best practices in distributing slide decks to external stakeholders

• Medical Information groups send slide decks in a reactive manner following an unsolicited request, specifically asking for slide decks on a particular topic.
• Off-label information is communicated reactively, typically in PDF format.
• Slide decks may be generated to handle frequently asked questions.

• About 75% of companies provide medical information to thought leaders, and more than half do so to clinical investigators.
• While a minority shares information with payers and formulary decision-makers, the growing importance of these groups would suggest that the number of companies providing data will grow in upcoming years.

I.	Executive Summary: Insights, Opportunities & Analysis	pp 3-6
	Summary findings	p. 4
	Benchmark class	p. 5
	Segmentation	p. 6
II.	Distribution of Medical Information	pp 7-25
	Criteria to determine the type of information to be shared
	Type of pipeline information to be shared
	Recipient stakeholder groups
	Factors considered before distributing the information
	Methods of distributing the information
III.	Protecting Medical Information	pp 26-29
	Types of protections used for slide decks
	Locking slide decks
IV.	Best Practices	pp 30-32
	Best practices in distributing slide decks
V.	Participant Demographics	pp 33-36
	Participant title
	Therapeutic areas
	Geographic span
VI.	Appendix	pp 37-55

• Use of slide decks for communicating off-label information to HCPs and other stakeholders
• Determination of the kind of off-label information that can be provided in a slide-deck format
• Criteria used to determine whether medical information is to be provided in PPT or PDF format
• Type of pipeline information provided via slide decks
• Stakeholder groups receiving medical information slide decks
• Information commonly shared with HCPs by large and small/mid-sized companies
• Information commonly shared with payers by large and small/mid-sized companies
• Information commonly shared with formulary decision makers by large and small/mid-sized companies
• Information commonly shared with clinical investigators by large and small/mid-sized companies
• Information commonly shared with contracted HCP speakers by large and small/mid-sized companies
• Information commonly shared with government agencies by large and small/mid-sized companies
• Takeaways of proactive vs. reactive sharing
• Type of information and stakeholder groups with whom medical information is shared proactively
• Type of information and stakeholder groups with whom medical information is shared reactively
• Information types sent via. slide decks
• Executive insights on proactive and reactive information sharing
• Most important internal and external factors influencing the use of slide decks for sharing information with external stakeholders
• Methods used to disseminate information and slide decks

• Types of protection used for slide decks and other medical information assets
• Use of locked vs. editable medical information slide decks
• Reasons for using locked or editable medical information slide decks

• Best practices in distributing slide decks to external stakeholders – Communicating reactively, and coordination with internal review functions
• Best practices in distributing slide decks to external stakeholders – Quality of information and alignment with stakeholder needs, and protection against inadvertent use

• Role of benchmark partners
• Therapeutic areas represented by benchmark companies
• Benchmark partners’ geographic span of responsibility

• Type of information shared in proactive or /and reactive manner with HCPs and clinical investigators within small/mid-sized companies
• Type of information shared in proactive or /and reactive manner with formulary decision makers and payers (non-HCPs) within small/mid-sized companies
• Type of information shared in proactive or /and reactive manner with contracted HCP speakers and government agencies within small/mid-sized companies
• Type of information shared in proactive or /and reactive manner with HCPs and clinical investigators within large companies
• Type of information shared in proactive or /and reactive manner with formulary decision makers and payers (non-HCPs) within large companies
• Type of information shared in proactive or /and reactive manner with contracted HCP speakers and government agencies within large companies
• Communication with HCPs at small/mid-sized companies
• Communication with payers at small/mid-sized companies
• Communication with formulary decision makers at small/mid-sized companies
• Communication with clinical investigators at small/mid-sized companies
• Communication with contracted HCP speakers at small/mid-sized companies
• Communication with government agencies at small/mid-sized companies
• Communication with HCPs at large companies
• Communication with payers at large companies
• Communication with formulary decision makers at large companies
• Communication with clinical investigators at large companies
• Communication with contracted HCP speakers at large companies
• Communication with government agencies at large companies